Rotavirus VP6 Recombinant Product does not contain a fusion partner.
Nature
Recombinant
Tag/Conjugate
Unconjugated
Alternative Names
Rotavirus; Rotavirus Vp6; RV; RV Vp6
Purity
> 90% pure. Multi-step procedure including affinity chromatography.
Format
Liquid
Concentration
Batch dependent - please inquire should you have specific requirements.
Buffer
50 mM Tris-HCl, pH8.0
Preservative
None
Storage
Store at 2-8°C for short term. Store at -20°C for long term. Avoid multiple freeze/thaw cycles
Introduction
Rotavirus is the most common cause of severe diarrhea among infants and young children. It is a genus of double-stranded RNA virus in the family Reoviridae. Nearly every child in the world has been infected with rotavirus at least once by the age of five. Immunity develops with each infection, so subsequent infections are less severe; adults are rarely affected. There are five species of this virus, referred to as A, B, C, D, and E. Rotavirus A, the most common species, causes more than 90% of rotavirus infections in humans.
Keywords
Rotavirus; Rotavirus Vp6; RV; RV Vp6
Citations
Publication ()
Have you cited DAGA-3002 in a publication? Let us know and earn a reward for your research.
Acute rotavirus infection is associated with the induction of circulating memory CD4+ T cell subsets
Chikondi Malamba-Banda, Chimwemwe Mhango, Prisca Benedicto-Matambo, Jonathan J Mandolo, End Chinyama, Orpha Kumwenda, Kayla G Barnes, Nigel A Cunliffe, Miren Iturriza-Gomara, Kondwani C Jambo, Khuzwayo C Jere
Applications: FCReactive species: Human
"Abstract: Strong CD4+ T cell-mediated immune protection following rotavirus infection has been observed in animal models, but its relevance in humans remains unclear. Here, we characterized acute and convalescent CD4+ T cell responses in children who were hospitalized with rotavirus-positive and rotavirus-negative diarrhoea in Blantyre, Malawi. Children presenting with laboratory-confirmed rotavirus infection had higher proportions of effector and central memory T helper 2 cells during acute infection i.e., at disease presentation compared to convalescence, 28 days post-infection defined by a follow-up 28 days after acute infection. However, circulating cytokine-producing (IFN-γ and/or TNF-α) rotavirus-specific VP6-specific CD4+ T cells were rarely detectable in children with rotavirus infection at both acute and convalescent stages. Moreover, following whole blood mitogenic stimulation, the responding CD4+ T cells were predominantly non-cytokine producers of IFN-γ and/or TNF-α. Our findings demonstrate limited induction of anti-viral IFN-γ and/or TNF-α-producing CD4+ T cells in rotavirus-vaccinated Malawian children following the development of laboratory-confirmed rotavirus infection."Article snippet: VP6 protein (DAGA-3002) was supplied by CD creative diagnostics, USA.
Figure 1. CD4+ T stimulations in children with or without rotavirus diarrhoea
Background
Rotaviruses belong to the Reoviridae family and are characterized by their double-stranded RNA genome and distinctive wheel-like appearance. VP6 is the most abundant protein in rotaviruses, accounting for about 51% of the total viral protein. It is localized in the middle layer of the capsid as the main structural protein, and VP6 exists as a trimer in the capsid of the virus particles. This layer provides stability and structural integrity to the virion, protecting the viral RNA genome from degradation and facilitating viral entry into host cells.
Figure 1. Schematic representation of a rotavirus virion. (Source: Shoja, Z. et al., 2022)
Researchers have discovered that VP6 possesses several characteristics that make it valuable in various fields of biomedicine, including targeted drug delivery, immunomodulation, diagnostics, and vaccine development. Rotavirus VP6 protein produced through recombinant techniques in E. coli has emerged as a valuable control in immunoassays and as an immunogen for various applications. As a control in immunoassays, recombinant rotavirus VP6 protein allows researchers to verify the specificity and sensitivity of their assays. By including VP6 protein as a known target, they can assess the performance and accuracy of their detection methods, ensuring reliable and reproducible results. Its use as a control helps to establish baseline measurements, validate assay conditions, and monitor assay performance over time. In addition, its immunogenic properties make it an effective candidate for stimulating an immune response in experimental settings. Researchers can utilize the recombinant rotavirus VP6 protein to immunize animals, generating antibodies specific to VP6. These antibodies can then be utilized in various applications, such as diagnostic assays, vaccine development, or further studies on the interaction between VP6 and the immune system.
Alternative Names
Recombinant Rotavirus Vp6 Recombinant RV Vp6 protein Rotavirus VP6 recombinant protein VP6 recombinant protein
References
1. Shoja Z, et al. Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials. Archives of Virology. 2022, 167(4): 1013-1023.
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Rotavirus VP6 as a potential vaccine candidate
Reviews in Medical Virology
Authors: Afchangi A, Jalilvand S, Mohajel N, et al.
By the age of 5 years, virtually all children have been infected by group A rotavirus (RVA), which is responsible for around half million mortality annually prior to vaccination. Relatively high rate of the morbidity and mortality highlights the necessity of applying preventive procedures particularly in developing countries. Two live attenuated RVA vaccines (Rotarix and RotaTeq) are licensed and now being used in many countries worldwide. Although these vaccines are shown to reduce the mortality up to 50%, several key questions yet remained to answer. Indeed, the licensed RV vaccines were found to be less effective in countries of sub-Saharan Africa and Southeast Asia. Therefore, developing next generation RVA vaccines is warranted. VP6 is highly abundant and conserved protein that forms the middle layer of RV particles and was shown to be both antigenic and immunogenic. Although it does not induce neutralizing antibodies, different VP6 preparations were found to induce homologous and cross-reactive immune responses with partial protection from RVA replication. Although the molecular mechanisms are not fully elucidated, VP6-based RVA vaccine candidates are worthy of further consideration. This review aims to focus on different aspects of VP6 protein and its potentiality for an alternative RV vaccine against RV disease.
COA
Publication 
Figure 1. Schematic representation of a rotavirus virion.
Loading ......
